Disclosed are means of inducing neuroregeneration and/or neuroprotection in patients with damage to the nervous system. In one embodiment, placenta derived CD34 positive cells are administered to a patient suffering from a neurological injury, said cells administered alone, or in combination with endothelial progenitor cells that are derived from placental sources. In one embodiment cells are manipulated to decrease immunogenicity by means of gene-editing or RNA interference inducing means. In another embodiment, neuroprotection and/or neuroregeneration is achieved by administration of exosomes derived from placental stem cells.
